How should we plan the future of nanomedicine for cancer diagnosis and therapy?

Int J Pharm. 2017 Nov 5;532(2):657-659. doi: 10.1016/j.ijpharm.2017.05.037. Epub 2017 May 19.

¹ Université Paris Descartes, Sorbonne-Paris-Cité, UTCBS, F-75006 Paris, France; CNRS, UTCBS UMR 8258, F-75006 Paris, France; INSERM, UTCBS U 1022, F-75006 Paris, France; Chimie ParisTech, PSL Research University, F-75005 Paris, France.
² Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, Université Grenoble Alpes, 38000 Grenoble, France.
³ Institut Galien Paris-Sud, CNRS, Université Paris-Sud, Université Paris-Saclay, Faculté de Pharmacie, 5, rue Jean-Baptiste Clément, 92296 Châtenay-Malabry, France.
⁴ Université Paris Descartes, Sorbonne-Paris-Cité, UTCBS, F-75006 Paris, France; CNRS, UTCBS UMR 8258, F-75006 Paris, France; INSERM, UTCBS U 1022, F-75006 Paris, France; Chimie ParisTech, PSL Research University, F-75005 Paris, France. Electronic address: nathalie.mignet@parisdescartes.fr.

No abstract available

Publication types